Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency

Investigational DNASE1L3 analog NTR-441, designed to degrade neutrophil extracellular traps (NETs), produced rapid clinical improvement in a treatment-refractory SLE patient. The report is a positive early signal for a novel mechanism-of-action in lupus, though it provides limited context on broader efficacy or durability.

Analysis

Investigational DNASE1L3 analog NTR-441, designed to degrade neutrophil extracellular traps (NETs), produced rapid clinical improvement in a treatment-refractory SLE patient. The report is a positive early signal for a novel mechanism-of-action in lupus, though it provides limited context on broader efficacy or durability.